OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2-advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors

被引：0
|
作者：
Pistilli, Barbara
Bellet, Meritxell
Del Mastro, Lucia
McArthur, Heather L.
Meisel, Jane Lowe
Schmid, Peter
Sohn, Joohyuk
De Kermadec, Elisabeth
Wei, Rachel
Chan, Arlene
机构：
[1] Gustave Roussy, Villejuif, France
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Vall Hebron Inst Oncol, Barcelona, Spain
[4] IRCCS Osped Policlinico San Martino Genoa, Dept Clin Oncol, Genoa, Italy
[5] UT SouthWestern Med Ctr, Dallas, TX USA
[6] Emory Univ, Winship Canter Inst, Atlanta, GA USA
[7] Queen Mary Univ London, Barts Canc Inst, London, England
[8] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med, Seoul, South Korea
[9] Olema Oncol, San Francisco, CA USA
[10] Breast Canc Res Ctr WA, Nedlands, WA, Australia
[11] Curtin Univ, Nedlands, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1135
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (BC)
    Finn, R. S.
    Crown, J. P.
    Lang, I.
    Boer, K.
    Bondarenko, I. M.
    Kulyk, S. O.
    Ettl, J.
    Patel, R.
    Pinter, T.
    Schmidt, M.
    Shparyk, Y.
    Thummala, A. R.
    Voytko, N. L.
    Breazna, A.
    Kim, S. T.
    Randolph, S.
    Slamon, D. J.
    CANCER RESEARCH, 2012, 72
  • [42] A phase I/II open-label, first-in-human, multicenter, dose escalation and dose expansion study of OP-1250 monotherapy in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer
    Hamilton, Erika
    Alemany, Carlos
    Lin, Nancy U.
    Klein, Pamela M.
    Trinh Le
    Kushner, Peter J.
    Harmon, Cyrus
    Zujewski, Jo Anne
    Patel, Manish
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
    Kalinsky, Kevin
    Bianchini, Giampaolo
    Hamilton, Erika P.
    Graff, Stephanie L.
    Park, Kyong Hwa
    Jeselsohn, Rinath
    Demirci, Umut
    Martin, Miguel
    Layman, Rachel M.
    Hurvitz, Sara A.
    Sammons, Sarah L.
    Kaufman, Peter A.
    Munoz, Montserrat
    Tseng, Ling-Ming
    Knoderer, Holly
    Nguyen, Bastien
    Zhou, Yanhong
    Ravenberg, Elizabeth
    Litchfield, Lacey M.
    Wander, Seth Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA1001 - LBA1001
  • [44] Real-world patient and practice characteristics associated with use of CDK4/6 inhibitors among patients receiving first therapy for HR+/HER2-advanced or metastatic breast cancer in Italy and Germany
    de Placido, S.
    Brucker, S.
    Law, E.
    Ajmera, M.
    Mitra, D.
    Davis, K. L.
    Harbeck, N.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S79 - S79
  • [45] Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2-locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
    Martin Jimenez, M.
    Lim, E.
    Mac Gregor, M. Chavez
    Bardia, A.
    Wu, J.
    Zhang, Q.
    Nowecki, Z.
    Cruz, F.
    Safin, R.
    Kim, S-B.
    Schem, C.
    Montero, A.
    Khan, S.
    Bandyopadhyay, R.
    Shivhare, M.
    Patre, M.
    Martinalbo, J.
    Roncoroni, L.
    Perez-Moreno, P. D.
    Sohn, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S633 - S634
  • [46] Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutation
    Goetz, Matthew
    Wander, Seth
    Bachelot, Thomas
    Batist, Gerald
    Cortes, Javier
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    de Nonneville, Alexandre
    Yam, Einav Nili-Gal
    Jhaveri, Komal
    Ma, Cynthia
    Parsons, Heather
    Rugo, Hope
    Sammons, Sarah
    Stover, Daniel
    Twelves, Chris
    Bardia, Aditya
    Plourde, Paul V.
    Portman, David J.
    Damodaran, Senthil
    CANCER RESEARCH, 2024, 84 (09)
  • [47] A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2)
    Loibl, Sibylle
    Park, Yeon
    Tolaney, Sara
    Gioni, Ioanna
    Johnston, Simon
    Klinowska, Teresa
    Mayer, Ingrid A.
    Nunes, Raquel
    Pistilli, Barbara
    Stuart, Mary
    Quintana, Angela
    Walding, Andrew
    Gnant, Michael
    CANCER RESEARCH, 2024, 84 (09)
  • [48] MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer
    Rastogi, Priya
    Toi, Masakazu
    Harbeck, Nadia
    Bourayou, Nawel
    Frenzel, Martin
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (04)
  • [49] Cardiovascular disease (CVD) and health care utilization (HCU) in patients (pts) with HR+, HER2 negative (HER2-) advanced breast cancer (ABC) on endocrine therapy with or without CDK4/6 inhibitor (CDK4/6i): A retrospective cohort study
    Dent, S.
    Alder, L.
    Broadwater, G.
    Hyslop, T.
    Oeffinger, K.
    Khouri, M.
    Balu, S.
    Kimmick, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S505 - S506
  • [50] Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).
    Pistilli, Barbara
    Wildiers, Hans
    Hamilton, Erika Paige
    Ferreira, Ana Alexandra
    Dalenc, Florence
    Vidal, Maria
    Gavila, Joaquin
    Goncalves, Anthony
    Murias, Carmen
    Mouret-Reynier, Marie-Ange
    Canon, Jean-Luc Re
    Bazan, Fernando
    Ladoire, Sylvain
    Sirulnik, L. Andres
    Bekradda, Mohamed
    Bol, Kees
    Stalbovskaya, Viktoriya
    Murat, Anastasia
    Ford, Jim
    Bidard, Francois Clement
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345